Complete remission of Sweet’s syndrome after azacytidine treatment for concomitant myelodysplastic syndrome

• Published in: International journal of hematology Vol. 99; no. 5; pp. 663 - 667
• Main Authors: Martinelli, Sara, Rigolin, Gian Matteo, Leo, Genesio, Gafà, Roberta, Lista, Enrico, Cibien, Francesca, Sofritti, Olga, Daghia, Giulia, Cavazzini, Francesco, Cuneo, Antonio
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.05.2014; Springer; Springer Nature B.V
• Subjects: Aged; Azacitidine - therapeutic use; Biological and medical sciences; Biopsy; Bone Marrow - pathology; Case Report; Dermatology; Hematologic and hematopoietic diseases; Hematology; Humans; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Medicine; Medicine & Public Health; Myelodysplastic Syndromes - complications; Myelodysplastic Syndromes - diagnosis; Myelodysplastic Syndromes - therapy; Oncology; Skin - pathology; Skin involvement in other diseases. Miscellaneous. General aspects; Sweet Syndrome - complications; Sweet Syndrome - diagnosis; Sweet Syndrome - drug therapy; Treatment Outcome; Azacytidine; Myelodysplastic syndromes; Sweet’s syndrome; Antineoplastic agent; Skin disease; Hematology; Malignant hemopathy; Myelodysplastic syndrome; Azanucleoside; Treatment; Antimetabolic; Neutrophilic dermatosis; Azacitidine; Triazine derivatives; Sweet's syndrome; Remission; Acute febrile neutrophilic dermatosis; Cancer
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-014-1527-9

Sweet’s syndrome is a rare condition with potentially disabling implications, characterized by painful skin lesions due to neutrophilic dermal infiltration and systemic inflammatory symptoms. A significant proportion of cases is malignancy associated. Hematologic neoplasms, particularly acute myeloid leukemia and myelodysplastic syndromes, are the most commonly associated malignant conditions. Here, we describe the first case of clinical remission of refractory Sweet’s syndrome following hypomethylating therapy with azacytidine in a patient with myelodysplastic syndrome who concurrently obtained a complete hematologic response.